Reference
1. Crompton J A , North D S , Minjung Y , et al. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs[J]. Journal of Antimicrobial Chemotherapy,2010,65(8):1784.
2. A.M. Casapao, T.P. Lodise, S.L. Davis, et al., Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis, Antimicrobial Agents and Chemotherapy. 2015, 59 (6): 2978–2985.
3. J.S. Davis, for the Australasian Society for Infectious Diseases Clinical Research N, A. Sud, et al., Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial, Clinical Infectious Diseases. 2016. 62 (2) :173–180.
4. A. Petrarca, C. Burant, U. Stiefel, et al., Outcomes of Bloodstream Infections (BSI) Caused by Coagulase-Negative Staphylococcus (CoNS) With Elevated Minimum Inhibitory Concentration (MIC) to Vancomycin at a Tertiary Care Veterans Affairs (VA) Medical Center, Open Forum Infectious Diseases. 2016.
5. McCormick M H, McGuire J M, Pittenger G E,et al.Vancomycin, a new antibiotic. I. Chemical and biologic properties[J]. Antibiot Annu,1955,3: 606-611.
6. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review[J]. American journal of health-system pharmacy. 2020,77(11)835-864.
7. Zhichao H, Junyan W, Kaifeng Q. Guidelines for clinical pharmacists for individualized administration of vancomycin [J]. Daily Medical Journal. 2015(2);78-82.
8. Jeffres M N, Isakow W , Doherty J A , et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia[J]. Clinical Therapeutics, 2007,29(6): 0-1115.
9. Carreno JJ, Jaworski A, Kenney RM, Davis SL. Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin. Infect DisTher,2013,2(2): 201-208.
10. Bruniera F R, Ferreira F M, Saviolli L R M, et al. The use of vancomycin with its therapeutic and adverse effects: a review[J]. 2015,19(4): 694-700.
11.Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy[J]. int j antimicrob agents, 2011, 37(2): 95-101.
12. Paediatric Formulary Committee. British National Formulary for Children 2011-2012. London, UK: Pharmaceutical Press; 2012.
13. Zhang M , Huang X L , Yahui W , et al. A rapid and simple UPLC method for serum vancomycin determination in pediatric patients undergoing continuous infusion or intermittent infusion of vancomycin[J]. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174: 214-219.
14. National Health and Family Planning Commission of China. the Guiding Principles of Clinical Use of Antibiotics. Official website of the National Health and Family Planning Commission ,China. 2015.
15. Forouzesh A, Moise PA, Sakoulas G. Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses[J]. Antimicrobial Agents & Chemotherapy, 53(2): 483-486.
16. H. Padari, K. Oselin, T. Tasa, et al., Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?. BMC Pediatrics. 16(1) (2016) 206
17. A. Hahn, R.W. Frenck Jr., M. Allen-Staat, et al., Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia, Therapeutic drug monitoring. 37 (5)(2015) 619-625.
18. Tafelski S , Nachtigall I , Troeger U, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application[J]. Journal of Infection and Public Health, 2015, 8(4):355-363.
19. Adriana C M , Evelina T , Elisabetta G , et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis[J]. Journal of Antimicrobial Chemotherapy 2012;67(1):17–24.
20. Zhao W, Zhang D, Fakhoury M, et a1. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease[J]. Antimicrob Agents Chemother, 2014,58(6): 3191-3199.
21. Cardoso Bourguignon da Silva, Dáfne, Toribio Finoti Seixas, Gláucia, Orlei RDA, et al. Vancomycin serum concentrations in pediatric oncologic/ hematologic intensive care patients[J]. Brazilian Journal of Infectious Diseases, 2012,16(4):361-365.
22. Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, et al. Telavancin and vancomycin pharmacodynamics with Staphylococcus au-reus in an in vitro dynamic model. J Antimicrob Chemother 2008; 62 :10651069.
23. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925–42.
24. A. Hahn, R.W. Frenck Jr., M. Allen-Staat, et al, Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia, Therapeutic drug monitoring. 37 (5)(2015) 619–625.
25. T raverso F , Peluffo M , Louge M, et al. Impact of methicillin resistance on mortality and surveillance of vancomycin susceptibility in bacteremias caused by Staphylococcus aureus[J]. Revista Argentina de microbiología, 2010, 42(4):274-278.
26. Kassim A , Omuse G , Premji Z , et al. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study[J]. Annals of Clinical Microbiology & Antimicrobials, 2016, 15(1):21.
27. He N, Su S, Ye ZK, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society[J]. Clin Infect Dis, 2020.71: S363-S371.
28 Verrall AJ, Ryan L, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections[J]. J Antimicrob Chemother, 2012, (12): 2970-2973.
29. Giulia DA, Adriana CM, Chiara DW, et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2014, (5): 1185-92.
30. Rhodes N J , Prozialeck W C , Lodise T P , et al. Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats[J]. Antimicrobial Agents & Chemotherapy, 2016;60(10):5742–5751.
31. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008 Apr;52(4):1330-6.